Mentice AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 129.89.
Mentice AB's Days Inventory for the
three
months ended in Mar. 2026 was 195.34.
Mentice AB's Days Payable for the
three
months ended in Mar. 2026 was 99.04.
Therefore, Mentice AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 226.19.
Mentice AB (OSTO:MNTC) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Mentice AB Cash Conversion Cycle Related Terms
Mentice AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Mentice AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MNTC vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Mentice AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Mentice AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Mentice AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (OSTO:MNTC) has a Cash Conversion Cycle of 226.19 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Mentice AB and its competitors.
Is Mentice AB's Cash Conversion Cycle too high?
Mentice AB's current Cash Conversion Cycle is 226.19. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Mentice AB's value of 226.19 is 44.1% above this industry median. Overall, Mentice AB has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Cash Conversion Cycle compare to ABT and SYK?
Mentice AB's Cash Conversion Cycle of 226.19 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Mentice AB's value of 226.19 is 44.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current Cash Conversion Cycle of 226.19 is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Cash Conversion Cycle is 226.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (OSTO:MNTC) is currently considered Possible Value Trap. The stock's GF Value™ is kr26.00, compared to a current price of kr13.05 — trading 49.8% below its estimated fair value. The current Cash Conversion Cycle is 226.19 and 44.1% above the Medical Devices & Instruments industry median of 156.96. Mentice AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Mentice AB (OSTO:MNTC), the current Cash Conversion Cycle is 226.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (OSTO:MNTC) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of kr13.05 is trading 49.8% below its estimated GF Value™ of kr26.00.
GuruFocus considers Mentice AB to be Possible Value Trap.
Key valuation signals for OSTO:MNTC:
Cash Conversion Cycle: 226.19
GF Value™: kr26.00 vs. price of kr13.05 (49.8% below fair value)
Industry Position: 44.1% above the Medical Devices & Instruments median
No single metric tells the full story. See the OSTO:MNTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
76GF Score
Get the complete analysis for OSTO:MNTC
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MNTC has been successfully added to your 
